Top

Published in:

Open Access 01-12-2006 | Review

Biomarkers in chronic adult hydrocephalus

Authors: Andrew Tarnaris, Laurence D Watkins, Neil D Kitchen

Published in: Fluids and Barriers of the CNS | Issue 1/2006

Abstract

Awareness of the importance of chronic adult hydrocephalus has been raised again with the recent emergence of epidemiological studies. It is estimated that between 5 and 10% of patients suffering from dementia might, in fact, have chronic hydrocephalus. Although, surgical diversion of the cerebrospinal fluid (CSF) represents the only known procedure able to treat the symptoms of this condition, the selection of surgical patients has always been problematic. In the last 40 years, we have become wiser in using appropriate diagnostic tests for the selection of these patients; however, the area of biological markers has so far been overlooked in this condition, in contrast to that for other neurodegenerative disorders and dementias. Biomarkers are biological substances that may be used to indicate either the onset or the presence, and the progression of a clinical condition, being closely linked to its pathophysiology. In such a setting they might assist in the more appropriate selection of patients for shunt surgery. In this article, we have reviewed research carried out in the last 25 years regarding the identification of serum and CSF biomarkers for chronic hydrocephalus, discussed the potential for each one, and finally discussed the limitations for use, as well as future directions and possibilities in this field. It is concluded that tumour-necrosis factor, tau protein, lactate, sulfatide and neurofilament triple protein are the most promising CSF markers for chronic hydrocephalus. At present however, none of these meet the criteria required to justify a change clinical practice. In the future, collaborative multi-centre projects will be needed to obtain more substantial data that overcome the problems that arise from small individual and uncoordinated studies.

Available only for authorised users

Vanneste J, van Acker R: Normal pressure hydrocephalus: did publications alter management?. J Neurol Neurosurg Psychiatry. 1990, 53 (7): 564-568.PubMedCentralPubMed

Larson EB, Reifler BV, Featherstone HJ, English DR: Dementia in elderly outpatients: a prospective study. Ann Intern Med. 1984, 100 (3): 417-423.PubMed

Tisell M, Hoglund M, Wikkelso C: National and regional incidence of surgery for adult hydrocephalus in Sweden. Acta Neurol Scand. 2005, 112 (2): 72-75. 10.1111/j.1600-0404.2005.00451.x.PubMed

Hoglund M, Tisell M, Wikkelso C: [Incidence of surgery for hydrocephalus in adults surveyed: same number afflicted by hydrocephalus as by multiple sclerosis]. Lakartidningen. 2001, 98 (14): 1681-1685.PubMed

Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, Oertel WH: Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol. 1995, 52 (10): 1017-1022.PubMed

Hakim S, Adams RD: The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci. 1965, 2 (4): 307-327. 10.1016/0022-510X(65)90016-X.PubMed

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001, 69 (3): 89-95. 10.1067/mcp.2001.113989.

Miller A, Glass-Marmor L, Abraham M, Grossman I, Shapiro S, Galboiz Y: Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin Neurol Neurosurg. 2004, 106 (3): 249-254. 10.1016/j.clineuro.2004.02.008.PubMed

Feigin A: Evidence from biomarkers and surrogate endpoints. NeuroRx. 2004, 1 (3): 323-330. 10.1602/neurorx.1.3.323.PubMedCentralPubMed

10.

Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C: Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006, 21 (1): 9-15. 10.1159/000089137.PubMed

11.

Andreasen N, Blennow K: CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg. 2005, 107 (3): 165-173. 10.1016/j.clineuro.2004.10.011.PubMed

12.

Rachakonda V, Pan TH, Le WD: Biomarkers of neurodegenerative disorders: how good are they?. Cell Res. 2004, 14 (5): 347-358. 10.1038/sj.cr.7290235.PubMed

13.

Teunissen CE, Dijkstra C, Polman C: Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005, 4 (1): 32-41. 10.1016/S1474-4422(04)00964-0.PubMed

14.

Avasarala JR: Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2004, 63 (3): 599; author reply 599-PubMed

15.

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol. 1995, 26 (3): 231-245.PubMed

16.

Del Bigio MR: Hydrocephalus-induced changes in the composition of cerebrospinal fluid. Neurosurgery. 1989, 25 (3): 416-423. 10.1097/00006123-198909000-00016.PubMed

17.

Sen J, Belli A, Petzold A, Russo S, Keir G, Thompson EJ, Smith M, Kitchen N: Extracellular fluid S100B in the injured brain: a future surrogate marker of acute brain injury?. Acta Neurochir (Wien). 2005, 147 (8): 897-900. 10.1007/s00701-005-0526-2.

18.

Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V: Serum S-100B protein in severe head injury. Neurosurgery. 1999, 45 (3): 477-483. 10.1097/00006123-199909000-00012.PubMed

19.

Davson H: The extracellular space of brain and cord. Physiology of the Cerebrospinal fluid. Edited by: Davson H. 1967, London , J & A Churchill, 112-113.

20.

Hammer M, Sorensen PS, Gjerris F, Larsen K: Vasopressin in the cerebrospinal fluid of patients with normal pressure hydrocephalus and benign intracranial hypertension. Acta Endocrinol (Copenh). 1982, 100 (2): 211-215.

21.

Sorensen PS, Gjerris F, Ibsen S, Bock E: Low cerebrospinal fluid concentration of brain-specific protein D2 in patients with normal pressure hydrocephalus. J Neurol Sci. 1983, 62 (1-3): 59-65. 10.1016/0022-510X(83)90189-2.PubMed

22.

Yamada N, Iwasa H, Mori S, Kurokawa N, Fujimoto K, Kawashima K, Masuzawa T: Melatonin secretion in normal pressure hydrocephalus after cerebral aneurysm rupture--investigation before and after ventriculoperitoneal shunt. Neurol Med Chir (Tokyo). 1991, 31 (8): 490-497.

23.

Wikkelso C, Blomstrand C: Cerebrospinal fluid proteins and cells in normal-pressure hydrocephalus. J Neurol. 1982, 228 (3): 171-180. 10.1007/BF00313729.PubMed

24.

Klinge P, Marmarou A, Bergsneider M, Relkin N, Black PM: Outcome of shunting in idiopathic normal-pressure hydrocephalus and the value of outcome assessment in shunted patients. Neurosurgery. 2005, 57 (3 Suppl): S40-52; discussion ii-v.PubMed

25.

Wikkelso C, Ekman R, Westergren I, Johansson B: Neuropeptides in cerebrospinal fluid in normal-pressure hydrocephalus and dementia. Eur Neurol. 1991, 31 (2): 88-93.PubMed

26.

Poca MA, Mataro M, Sahuquillo J, Catalan R, Ibanez J, Galard R: Shunt related changes in somatostatin, neuropeptide Y, and corticotropin releasing factor concentrations in patients with normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry. 2001, 70 (3): 298-304. 10.1136/jnnp.70.3.298.PubMedCentralPubMed

27.

Rubinow DR, Davis CL, Post RM: Somatostatin in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 1988, 12 Suppl: S137-55. 10.1016/0278-5846(88)90077-2.PubMed

28.

Ehara K, Matsumoto S, Yoshida N, Kuno T, Tanaka C: Ascending norepinephrine pathways impaired in experimental hydrocephalus. Jpn J Pharmacol. 1982, 32 (1): 205-208.PubMed

29.

Molins A, Catalan R, Sahuquillo J, Castellanos JM, Codina A, Galard R: Somatostatin cerebrospinal fluid levels in dementia. J Neurol. 1991, 238 (3): 168-170. 10.1007/BF00319684.PubMed

30.

Schettini G: Brain somatostatin: receptor-coupled transducing mechanisms and role in cognitive functions. Pharmacol Res. 1991, 23 (3): 203-215. 10.1016/S1043-6618(05)80080-5.PubMed

31.

Wikkelso C, Fahrenkrug J, Blomstrand C, Johansson BB: Dementia of different etiologies: vasoactive intestinal polypeptide in CSF. Neurology. 1985, 35 (4): 592-595.PubMed

32.

Henning RJ, Sawmiller DR: Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res. 2001, 49 (1): 27-37. 10.1016/S0008-6363(00)00229-7.PubMed

33.

Tullberg M, Mansson JE, Fredman P, Lekman A, Blennow K, Ekman R, Rosengren LE, Tisell M, Wikkelso C: CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry. 2000, 69 (1): 74-81. 10.1136/jnnp.69.1.74.PubMedCentralPubMed

34.

Sutton LN, Wood JH, Brooks BR, Barrer SJ, Kline M, Cohen SR: Cerebrospinal fluid myelin basic protein in hydrocephalus. J Neurosurg. 1983, 59 (3): 467-470.PubMed

35.

Tisell M, Tullberg M, Mansson JE, Fredman P, Blennow K, Wikkelso C: Differences in cerebrospinal fluid dynamics do not affect the levels of biochemical markers in ventricular CSF from patients with aqueductal stenosis and idiopathic normal pressure hydrocephalus. Eur J Neurol. 2004, 11 (1): 17-23. 10.1046/j.1351-5101.2003.00698.x.PubMed

36.

Catalan R, Sahuquillo J, Poca MA, Molins A, Castellanos JM, Galard R: Neuropeptide Y cerebrospinal fluid levels in patients with normal pressure hydrocephalus syndrome. Biol Psychiatry. 1994, 36 (1): 61-63. 10.1016/0006-3223(94)90064-7.PubMed

37.

Alom J, Galard R, Catalan R, Castellanos JM, Schwartz S, Tolosa E: Cerebrospinal fluid neuropeptide Y in Alzheimer's disease. Eur Neurol. 1990, 30 (4): 207-210.PubMed

38.

Malm J, Kristensen B, Ekstedt J, Adolfsson R, Wester P: CSF monoamine metabolites, cholinesterases and lactate in the adult hydrocephalus syndrome (normal pressure hydrocephalus) related to CSF hydrodynamic parameters. J Neurol Neurosurg Psychiatry. 1991, 54 (3): 252-259.PubMedCentralPubMed

39.

Hildebrand J, Moussa Z, Raftopoulos C, Vanhouche J, Laute MA, Przedborski S: Variations of homovanillic acid levels in ventricular cerebrospinal fluid. Acta Neurol Scand. 1992, 85 (5): 340-342.PubMed

40.

Spanu G, Santagostino G, Marzatico F, Gaetani P, Silvani V, Rodriguez y Baena R: Idiopathic hydrocephalic dementia in aging brain the neurosurgical approach. Funct Neurol. 1989, 4 (3): 293-298.PubMed

41.

Nooijen PT, Schoonderwaldt HC, Wevers RA, Hommes OR, Lamers KJ: Neuron-specific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia. Dement Geriatr Cogn Disord. 1997, 8 (3): 169-173.PubMed

42.

Fersten E, Gordon-Krajcer W, Glowacki M, Mroziak B, Jurkiewicz J, Czernicki Z: Cerebrospinal fluid free-radical peroxidation products and cognitive functioning patterns differentiate varieties of normal pressure hydrocephalus. Folia Neuropathol. 2004, 42 (3): 133-140.PubMed

43.

Blennow K, Wallin A, Ekman R: Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders?. J Neural Transm Park Dis Dement Sect. 1994, 8 (3): 183-191. 10.1007/BF02260939.PubMed

44.

Parnetti L, Palumbo B, Cardinali L, Loreti F, Chionne F, Cecchetti R, Senin U: Cerebrospinal fluid neuron-specific enolase in Alzheimer's disease and vascular dementia. Neurosci Lett. 1995, 183 (1-2): 43-45. 10.1016/0304-3940(94)11110-5.PubMed

45.

Sutton R, Keohane ME, VanderBerg SR, Gonias SL: Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis. 1994, 5 (2): 167-171.PubMed

46.

Hansen A, Whitelaw A, Lapp C, Brugnara C: Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus. Acta Paediatr. 1997, 86 (9): 995-998.PubMed

47.

Hansen AR, Lapp C, Brugnara C: Plasminogen activator inhibitor-1: defining characteristics in the cerebrospinal fluid of newborns. J Pediatr. 2000, 137 (1): 132-134. 10.1067/mpd.2000.106229.PubMed

48.

Mase M, Yamada K, Shimazu N, Seiki K, Oda H, Nakau H, Inui T, Li W, Eguchi N, Urade Y: Lipocalin-type prostaglandin D synthase (beta-trace) in cerebrospinal fluid: a useful marker for the diagnosis of normal pressure hydrocephalus. Neurosci Res. 2003, 47 (4): 455-459. 10.1016/j.neures.2003.08.009.PubMed

49.

Levin SD, Hoyle NR, Brown JK, Thomas DG: Cerebrospinal fluid myelin basic protein immunoreactivity as an indicator of brain damage in children. Dev Med Child Neurol. 1985, 27 (6): 807-813.PubMed

50.

Whitaker JN, Lisak RP, Bashir RM, Fitch OH, Seyer JM, Krance R, Lawrence JA, Ch'ien LT, O'Sullivan P: Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann Neurol. 1980, 7 (1): 58-64. 10.1002/ana.410070111.PubMed

51.

Longatti PL, Canova G, Guida F, Carniato A, Moro M, Carteri A: The CSF myelin basic protein: a reliable marker of actual cerebral damage in hydrocephalus. J Neurosurg Sci. 1993, 37 (2): 87-90.PubMed

52.

Fukushima N, Yokouchi K, Kawagishi K, Ren G, Higashiyama F, Moriizumi T: Proliferating cell populations in experimentally-induced hydrocephalus in developing rats. J Clin Neurosci. 2003, 10 (3): 334-337. 10.1016/S0967-5868(03)00019-5.PubMed

53.

Del Bigio MR, Cardoso ER, Halliday WC: Neuropathological changes in chronic adult hydrocephalus: cortical biopsies and autopsy findings. Can J Neurol Sci. 1997, 24 (2): 121-126.PubMed

54.

Sendrowski K, Sobaniec W, Sobaniec-Lotowska ME, Lewczuk P: S-100 protein as marker of the blood-brain barrier disruption in children with internal hydrocephalus and epilepsy--a preliminary study. Rocz Akad Med Bialymst. 2004, 49 Suppl 1: 236-238.PubMed

55.

Migheli A, Cordera S, Bendotti C, Atzori C, Piva R, Schiffer D: S-100beta protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett. 1999, 261 (1-2): 25-28. 10.1016/S0304-3940(98)01001-5.PubMed

56.

Mashayekhi F, Salehi Z: Expression of nerve growth factor in cerebrospinal fluid of congenital hydrocephalic and normal children. Eur J Neurol. 2005, 12 (8): 632-637. 10.1111/j.1468-1331.2005.01044.x.PubMed

57.

Shinoda M, Hidaka M, Lindqvist E, Soderstrom S, Matsumae M, Oi S, Sato O, Tsugane R, Ebendal T, Olson L: NGF, NT-3 and Trk C mRNAs, but not TrkA mRNA, are upregulated in the paraventricular structures in experimental hydrocephalus. Childs Nerv Syst. 2001, 17 (12): 704-712. 10.1007/s00381-001-0515-6.PubMed

58.

Yang JT, Chang CN, Hsu YH, Wei KC, Lin TK, Wu JH: Increase in CSF NGF concentration is positively correlated with poor prognosis of postoperative hydrocephalic patients. Clin Biochem. 1999, 32 (8): 673-675. 10.1016/S0009-9120(99)00077-6.PubMed

59.

Hochhaus F, Koehne P, Schaper C, Butenandt O, Felderhoff-Mueser U, Ring-Mrozik E, Obladen M, Buhrer C: Elevated nerve growth factor and neurotrophin-3 levels in cerebrospinal fluid of children with hydrocephalus. BMC Pediatr. 2001, 1: 2-10.1186/1471-2431-1-2.PubMedCentralPubMed

60.

Kudo T, Mima T, Hashimoto R, Nakao K, Morihara T, Tanimukai H, Tsujio I, Koike Y, Tagami S, Mori H, Nakamura Y, Tanaka T, Mori K, Takeda M: Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin Neurosci. 2000, 54 (2): 199-202. 10.1046/j.1440-1819.2000.00658.x.PubMed

61.

Newman J, Rissman RA, Sarsoza F, Kim RC, Dick M, Bennett DA, Cotman CW, Rohn TT, Head E: Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol (Berl). 2005, 110 (2): 135-144. 10.1007/s00401-005-1027-3.

62.

Van Everbroeck B, Boons J, Cras P: Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease. Clin Neurol Neurosurg. 2005, 107 (5): 355-360. 10.1016/j.clineuro.2004.12.002.PubMed

63.

Lins H, Wichart I, Bancher C, Wallesch CW, Jellinger KA, Rosler N: Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. J Neural Transm. 2004, 111 (3): 273-280. 10.1007/s00702-003-0075-x.PubMed

64.

Samuels SC, Silverman JM, Marin DB, Peskind ER, Younki SG, Greenberg DA, Schnur E, Santoro J, Davis KL: CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology. 1999, 52 (3): 547-551.PubMed

65.

Klinge PM, Samii A, Niescken S, Brinker T, Silverberg GD: Brain amyloid accumulates in aged rats with kaolin-induced hydrocephalus. Neuroreport. 2006, 17 (6): 657-660. 10.1097/00001756-200604240-00020.PubMed

66.

Bartosik-Psujek H, Stelmasiak Z: Biochemical markers of damage of the central nervous system in multiple sclerosis. Ann Univ Mariae Curie Sklodowska [Med]. 2001, 56: 389-392.

67.

Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J: Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003, 61: 1720-1725.PubMed

68.

Tullberg M, Rosengren L, Blomsterwall E, Karlsson JE, Wikkelso C: CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology. 1998, 50 (4): 1122-1127.PubMed

69.

Albrechtsen M, Sorensen PS, Gjerris F, Bock E: High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus. J Neurol Sci. 1985, 70 (3): 269-274. 10.1016/0022-510X(85)90168-6.PubMed

70.

Lacoste-Royal G, Mathieu M, Nalbantoglu J, Julien JP, Gauthier S, Gauvreau D: Lack of association between two restriction fragment length polymorphisms in the genes for the light and heavy neurofilament proteins and Alzheimer's disease. Can J Neurol Sci. 1990, 17 (3): 302-305.PubMed

71.

Marcus J, Honigbaum S, Shroff S, Honke K, Rosenbluth J, Dupree JL: Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia. 2006, 53 (4): 372-381. 10.1002/glia.20292.PubMed

72.

Kovacs T, Szirmai I, Papp M: [Clinico-pathology and differential diagnosis of Binswanger's disease]. Ideggyogy Sz. 2005, 58 (3-4): 78-87.PubMed

73.

Tarkowski E, Tullberg M, Fredman P, Wikkelso C: Normal pressure hydrocephalus triggers intrathecal production of TNF-alpha. Neurobiol Aging. 2003, 24 (5): 707-714. 10.1016/S0197-4580(02)00187-2.PubMed

74.

Stoeck K, Bodemer M, Ciesielczyk B, Meissner B, Bartl M, Heinemann U, Zerr I: Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Arch Neurol. 2005, 62 (10): 1591-1594. 10.1001/archneur.62.10.1591.PubMed

75.

Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E: Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol. 1991, 13 (7): 455-458.PubMed

76.

Mollereau C, Roumy M, Zajac JM: Opioid-modulating peptides: mechanisms of action. Curr Top Med Chem. 2005, 5 (3): 341-355. 10.2174/1568026053544515.PubMed

77.

Galard R, Poca MA, Catalan R, Tintore M, Castellanos JM, Sahuquillo J: Decreased cholecystokinin levels in cerebrospinal fluid of patients with adult chronic hydrocephalus syndrome. Biol Psychiatry. 1997, 41 (7): 804-809. 10.1016/S0006-3223(96)00098-4.PubMed

78.

Brettschneider J, Riepe MW, Petereit HF, Ludolph AC, Tumani H: Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus?. J Neurol Neurosurg Psychiatry. 2004, 75 (11): 1614-1616. 10.1136/jnnp.2003.026013.PubMedCentralPubMed

79.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001, 58 (3): 373-379. 10.1001/archneur.58.3.373.PubMed

80.

Michell AW, Lewis SJ, Foltynie T, Barker RA: Biomarkers and Parkinson's disease. Brain. 2004, 127 (Pt 8): 1693-1705. 10.1093/brain/awh198.PubMed

81.

Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M: Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2005, 19 (2-3): 164-170. 10.1159/000083178.PubMed

82.

Bech RA, Waldemar G, Gjerris F, Klinken L, Juhler M: Shunting effects in patients with idiopathic normal pressure hydrocephalus; correlation with cerebral and leptomeningeal biopsy findings. Acta Neurochir (Wien). 1999, 141 (6): 633-639. 10.1007/s007010050353.

83.

Savolainen S, Hurskainen H, Paljarvi L, Alafuzoff I, Vapalahti M: Five-year outcome of normal pressure hydrocephalus with or without a shunt: predictive value of the clinical signs, neuropsychological evaluation and infusion test. Acta Neurochir (Wien). 2002, 144 (6): 515-23; discussion 523. 10.1007/s00701-002-0936-3.

84.

Holm A, Savolainen S, Alafuzoff I: Brain biopsy prior to treatment of Alzheimer's disease. Minim Invasive Neurosurg. 2003, 46 (3): 161-164. 10.1055/s-2003-40733.PubMed

85.

Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D: Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2003, 2 (8): 506-511. 10.1016/S1474-4422(03)00487-3.PubMed

86.

Silverberg GD, Levinthal E, Sullivan EV, Bloch DA, Chang SD, Leverenz J, Flitman S, Winn R, Marciano F, Saul T, Huhn S, Mayo M, McGuire D: Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology. 2002, 59 (8): 1139-1145.PubMed

87.

Akai K, Uchigasaki S, Tanaka U, Komatsu A: Normal pressure hydrocephalus. Neuropathological study. Acta Pathol Jpn. 1987, 37 (1): 97-110.PubMed

88.

Weller RO, Wisniewski H, Shulman K, Terry RD: Experimental hydrocephalus in young dogs: histological and ultrastructural study of the brain tissue damage. J Neuropathol Exp Neurol. 1971, 30 (4): 613-626.PubMed

89.

Miyagami M, Murakami T, Wakamatsu K, Kondo T, Takeuchi T, Tsubokawa T, Moriyasu N: Experimental and clinical studies on prognosis deteriorating factors in the acute stage of intraventricular hemorrhage. Neurol Med Chir (Tokyo). 1981, 21 (1): 75-83.

90.

James AEJ, Flor WJ, Novak GR, Ribas JL, Parker JL, Sickel WL: The ultrastructural basis of periventricular edema: preliminary studies. Radiology. 1980, 135 (3): 747-750.PubMed

91.

Klinge PM, Samii A, Muhlendyck A, Visnyei K, Meyer GJ, Walter GF, Silverberg GD, Brinker T: Cerebral hypoperfusion and delayed hippocampal response after induction of adult kaolin hydrocephalus. Stroke. 2003, 34 (1): 193-199. 10.1161/01.STR.0000048820.17198.15.PubMed

92.

Klinge P, Muhlendyck A, Lee S, Ludemann W, Groos S, Samii M, Brinker T: Temporal and regional profile of neuronal and glial cellular injury after induction of kaolin hydrocephalus. Acta Neurochir Suppl. 2002, 81: 275-277.PubMed

93.

Del Bigio MR, Zhang YW: Cell death, axonal damage, and cell birth in the immature rat brain following induction of hydrocephalus. Exp Neurol. 1998, 154 (1): 157-169. 10.1006/exnr.1998.6922.PubMed

94.

Gelling L, Iddon J, McVicar A, Pickard JD: CSF circulation disorders: measuring progress in patients through quality of life and hope. J Clin Nurs. 2004, 13 (5): 589-600. 10.1111/j.1365-2702.2004.00910.x.PubMed

95.

Kondziella D, Qu H, Ludemann W, Brinker T, Sletvold O, Sonnewald U: Astrocyte metabolism is disturbed in the early development of experimental hydrocephalus. J Neurochem. 2003, 85 (1): 274-281.PubMed

96.

Ishikawa M: Clinical guidelines for idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo). 2004, 44 (4): 222-223. 10.2176/nmc.44.222.

97.

Reiber H: Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998, 4 (3): 99-107. 10.1191/135245898678909439.PubMed

98.

Wood JH: Neurochemical analysis of cerebrospinal fluid. Neurology. 1980, 30 (6): 645-651.PubMed

99.

van Engelen BG, Lamers KJ, Gabreels FJ, Wevers RA, van Geel WJ, Borm GF: Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem. 1992, 38 (6): 813-816.PubMed

100.

Gjerris A, Werdelin L, Gjerris F, Sorensen PS, Rafaelsen OJ, Alling C: CSF-amine metabolites in depression, dementia and in controls. Acta Psychiatr Scand. 1987, 75 (6): 619-628.PubMed

101.

Gjerris A, Gjerris F, Sorensen PS, Sorensen EB, Christensen NJ, Fahrenkrug J, Rehfeld JF: Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level?. Acta Neurochir (Wien). 1988, 91 (1-2): 55-59. 10.1007/BF01400529.

102.

Reiber H: Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta. 2001, 310 (2): 173-186. 10.1016/S0009-8981(01)00573-3.PubMed

103.

Luedemann W, Kondziella D, Tienken K, Klinge P, Brinker T, Berens von Rautenfeld D: Spinal cerebrospinal fluid pathways and their significance for the compensation of kaolin-hydrocephalus. Acta Neurochir Suppl. 2002, 81: 271-273.PubMed

104.

Agren-Wilsson A, Roslin M, Eklund A, Koskinen LO, Bergenheim AT, Malm J: Intracerebral microdialysis and CSF hydrodynamics in idiopathic adult hydrocephalus syndrome. J Neurol Neurosurg Psychiatry. 2003, 74 (2): 217-221. 10.1136/jnnp.74.2.217.PubMedCentralPubMed

105.

Agren-Wilsson A, Eklund A, Koskinen LO, Bergenheim AT, Malm J: Brain energy metabolism and intracranial pressure in idiopathic adult hydrocephalus syndrome. J Neurol Neurosurg Psychiatry. 2005, 76 (8): 1088-1093. 10.1136/jnnp.2004.042838.PubMedCentralPubMed

106.

Geracioti TDJ, Orth DN, Ekhator NN, Blumenkopf B, Loosen PT: Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab. 1992, 74 (6): 1325-1330. 10.1210/jc.74.6.1325.PubMed

107.

Woertgen C, Albert R, Kohler M, Rzepecki A, Rothoerl RD, Bein T, Brawanski A: Ventricular tapping seems to have no influence on S-100B and NSE serum concentrations. Neurosurg Rev. 2004, 27 (3): 178-180. 10.1007/s10143-004-0341-x.PubMed

108.

Kruse A, Cesarini KG, Bach FW, Persson L: Increases of neuron-specific enolase, S-100 protein, creatine kinase and creatine kinase BB isoenzyme in CSF following intraventricular catheter implantation. Acta Neurochir (Wien). 1991, 110 (3-4): 106-109. 10.1007/BF01400675.

109.

Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, Williams KL: Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev. 1996, 13: 19-50.PubMed

110.

Wenner BR, Lovell MA, Lynn BC: Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res. 2004, 3 (1): 97-103. 10.1021/pr034070r.PubMed

111.

Finehout EJ, Franck Z, Lee KH: Towards two-dimensional electrophoresis mapping of the cerebrospinal fluid proteome from a single individual. Electrophoresis. 2004, 25 (15): 2564-2575. 10.1002/elps.200406012.PubMed

112.

Maccarrone G, Milfay D, Birg I, Rosenhagen M, Holsboer F, Grimm R, Bailey J, Zolotarjova N, Turck CW: Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis. 2004, 25 (14): 2402-2412. 10.1002/elps.200305909.PubMed

113.

Yuan X, Desiderio DM: Human cerebrospinal fluid peptidomics. J Mass Spectrom. 2005, 40 (2): 176-181. 10.1002/jms.737.PubMed

114.

Yuan X, Desiderio DM: Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics. 2005, 5 (2): 541-550. 10.1002/pmic.200400934.PubMed

115.

Berger JR, Avison M, Mootoor Y, Beach C: Cerebrospinal fluid proteomics and human immunodeficiency virus dementia: preliminary observations. J Neurovirol. 2005, 11 (6): 557-562. 10.1080/13550280500385237.PubMed

116.

Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, Gilden DH: Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler. 2004, 10 (3): 245-260. 10.1191/1352458504ms1023oa.PubMed

117.

Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003, 118 (1-2): 140-146. 10.1016/j.molbrainres.2003.08.005.PubMed

118.

Zheng PP, Luider TM, Pieters R, Avezaat CJ, van den Bent MJ, Sillevis Smitt PA, Kros JM: Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol. 2003, 62 (8): 855-862.PubMed

119.

Li X, Miyajima M, Mineki R, Taka H, Murayama K, Arai H: Analysis of cerebellum proteomics in the hydrocephalic H-Tx rat. Neuroreport. 2005, 16 (6): 571-574. 10.1097/00001756-200504250-00011.PubMed

120.

Burlet-Schiltz O, Mazarguil H, Sol JC, Chaynes P, Monsarrat B, Zajac JM, Roussin A: Identification of neuropeptide FF-related peptides in human cerebrospinal fluid by mass spectrometry. FEBS Lett. 2002, 532 (3): 313-318. 10.1016/S0014-5793(02)03686-4.PubMed

Title: Biomarkers in chronic adult hydrocephalus
Authors: Andrew Tarnaris
Laurence D Watkins
Neil D Kitchen
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: Fluids and Barriers of the CNS / Issue 1/2006
Electronic ISSN: 2045-8118
DOI: https://doi.org/10.1186/1743-8454-3-11

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Biomarkers in chronic adult hydrocephalus

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Uneven distribution of nucleoside transporters and intracellular enzymatic degradation prevent transport of intact [14C] adenosine across the sheep choroid plexus epithelium as a monolayer in primary culture

Li JK: Neural Tube Defects – From Origin to Treatment Edited by: Diego F Wyszynski. Oxford University Press, New York; 2006.

Risk factors for pressure sores in adult patients with myelomeningocele – a questionnaire-based study

A reproductive history of mothers with spina bifida offspring-a new look at old issues

In vitro hydrodynamic properties of the Miethke proGAV hydrocephalus shunt

Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis